ClinConnect ClinConnect Logo
Search / Trial NCT04624490

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Launched by MARIO CASTRO, MD, MPH · Nov 5, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Hyperpolarized 129 Xe Mri

ClinConnect Summary

This clinical trial is looking at a new way to see how well lungs are working using a special type of MRI with a gas called hyperpolarized (HP) 129Xe. The goal is to find out if this imaging technique can help doctors better understand lung function, especially in people with conditions like asthma, COPD, cystic fibrosis, and other lung diseases. The study is currently recruiting participants, which includes both healthy volunteers and those diagnosed with lung diseases.

To be eligible for this trial, healthy volunteers must not have any lung conditions and should be able to read and understand English or Spanish. Those with lung diseases need to have a diagnosis from a doctor and should not have experienced a serious worsening of their lung function in the past month. Participants can expect to undergo MRI scans where they will need to hold their breath for about 15-16 seconds. It's important to know that certain factors, such as being pregnant or having specific health issues, may prevent someone from participating in the study. This research could lead to better ways to assess and treat lung conditions in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Healthy Volunteers:
  • Subject has no diagnosed pulmonary conditions
  • Ability to read and understand English or Spanish
  • Subjects with Lung Disease:
  • Subject has a diagnosis of pulmonary dysfunction made by a physician
  • No acute worsening of pulmonary function in the past 30 days
  • Ability to read and understand English or Spanish
  • Exclusion Criteria:
  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Subject does not fit into 129Xe vest coil used for MRI
  • Subject cannot hold his/her breath for 15-16 seconds
  • Subject deemed unlikely to be able to comply with instructions during imaging
  • Oxygen saturation \<88% on room air or with supplemental oxygen
  • Cognitive deficits that preclude ability to provide consent
  • Institutionalization

About Mario Castro, Md, Mph

Dr. Mario Castro, MD, MPH, is a distinguished clinical trial sponsor with extensive expertise in respiratory medicine and public health. With a robust background in conducting innovative research, Dr. Castro is dedicated to advancing medical knowledge and improving patient outcomes through rigorous clinical investigations. His commitment to ethical standards and patient safety, combined with his leadership in multidisciplinary teams, ensures the successful execution of clinical trials that address critical health challenges. Dr. Castro's contributions to the field are marked by his passion for translating research findings into practical applications that enhance healthcare delivery and efficacy.

Locations

Kansas City, Kansas, United States

Patients applied

0 patients applied

Trial Officials

Peter Niedbalski, PHD

Principal Investigator

University of Kansas Medical Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials